| ZOGENIX | FORM NO: ZMA-IIS-CRS-001 | EFFECTIVE DATE: 5/1/2015 |
|---|-----------------------------|--------------------------|
| ISSUED BY: Medical Affairs Department PAGE: 1 | | |
| SUBJECT: Investigator Initiated & Collaborative Research Study Proposal Submission Form | | |

Instructions:

This form should be used to provide the committee with a summary of the proposed study for review and comment prior to submitting a formal protocol. Please fill out completely and submit via email along with a copy of your CV to Zogenix **Medical Affairs**:

Zogenix, Inc. E-mail: IIS@Zogenix.com

Institution/Organization Information:

Princip Investigator:

| Tax ID: | - |
|---|---|
| Co-Investigator(s) (if applicable): | |
| Phone: | |
| Institution or Practice Name: | |
| Address: | |
| E-mail: | |
| Stu | udy Information: |
| STUDY DRUG: (check the appropriate response) | □ ZX008 (fenfluramine) |
| | ☐ Non-drug study (i.e. observational study, retrospective database study) |
| STUDY TITLE: | |
| | |
| STUDY OVERVIEW: (please include description of the study concept and key objective(s), of the trial. | |
| | |
| | |
| | |
| | |

| ZOGENIX | FORM NO: ZMA-IIS-CRS-001 | EFFECTIVE DATE: 5/1/2015 |
|---|-----------------------------|--------------------------------|
| ISSUED BY: Medical Affairs Department PAGE: 2 | | |
| SUBJECT: Investigator Initiated & Collaborative Research Study Proposal Submission Form | | |

| STUDY SUBJECTS: (i.e. sex, age group, diagnosis, etc.) | |
|---|--|
| DESIGN: (check all that apply) | □ Single-dose □ Multiple-dose □ Randomized □ Non-randomized □ Blinded: □ single-blind or □ double blind □ Parallel □ Cross-over □ Single-site □ Multiple-site □ (if none of the above apply to your study, please briefly describe the design in the space below): |
| DURATION OF STUDY (i.e. how long will patients be treated or what period of time will be covered in a retrospective or observational study) | Weeks Months |



| | TREATMENT PERIOD: (Briefly describe how patients will be handled during the treatment period.) | |
|----------------------|--|--|
| 1. 2. 3. 4. | Include: Inclusion/exclusion criteria # of visits, Outcome assessment tools (pain measures, QOL measures, etc.), Dose titration (if applicable), Adverse event monitoring | |
| | ATTACH EXTRA SHEET IF NEEDED. | |
| | NOTE: If there is no Treatment being tested as in the case of an observational study or restrospective database study, etc., please use this space to describe your methodology. | |
| | | |
| | | |
| | | |
| | | |
| | LOCATION: (i.e. name of clinic/office, address, phone, fax, etc.) | |
| | NO. OF SUBJECTS: (Number of subjects you think will meet inclusion criteria within the allowed enrollment period or number of subjects that will be included in your observational study, retrospective study, etc.) | |
| | EFFICACY: (Primary and/or secondary efficacy outcomes.(i.e. reduction in seizure frequency, sleep quality, behavioral outcomes, quality of life, etc.) ATTACH EXTRA SHEET IF NEEDED. | |
| | | |

| ZOGENIX | FORM NO: ZMA-IIS-CRS-001 | EFFECTIVE DATE: 5/1/2015 | | | |
|---|-----------------------------|--------------------------------|--|--|--|
| | | 5/1/2015 | | | |
| ISSUED BY: Medical Affairs Department | PAGE: 4 | | | | |
| SUBJECT: Investigator Initiated & Collaborative Research Study Proposal Submission Form | | | | | |
| | | | | | |
| | | | | | |
| SAFETY: (How and when will safety be assessed or adverse events be monitored) | | | | | |
| | | | | | |
| ESTIMATED BUDGET: (Provide a rough estimate as we understand that the final budget cannot be determined until a full protocol is developed) | | | | | |
| Contact Information & Signature of Individual Submitting Study Proposal: Name: | | | | | |
| Email: | | | | | |
| Title: | | | | | |
| Phone: | | | | | |
| Study Submission Date: | | | | | |
| Signature of Individual Submitting Study Proposal: | | | | | |